Dec 05, 2012, 11.07 AM | Source: PTI
The Supreme Court today reserved its order on Swiss pharma giant Novartis AG's plea for getting its blood cancer drug Glivec patented in India.
A bench of justices Aftab Alam and Ranajan Prakash Desai reserved its verdict after marathon arguments which went on for months.
Novartis approached the apex court challenging the order of Chennai-based Intellectual Property Appellate Board (IPAB), which rejected its appeal against patent department's decision on Glivec.
The Comptroller General of Patent and Design had denied patent to Glivec on several grounds including its alleged failure to meet stipulations under sections 3(d) and 3(b) of the Indian Patent Law.
Section 3(d) restricts patents for already known drugs unless the new claims are superior in terms of efficacy.
Section 3(b) restricts patents for products that are against public interest and do not demonstrate enhanced efficacy over existing products.
Global drug major Novartis has invested, expanded
The 2016 Special 301 Report continued with the pla
Being leaders in healthcare, Novartis will be work
Novartis India at its meeting held on February 03,
Novartis India Ltd has informed BSE that the meeti